Macular Degeneration Treatment Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Macular degeneration treatment encompasses pharmaceutical and surgical interventions for age-related macular degeneration (AMD), the leading cause of vision loss among older adults. The market is divided between wet (neovascular) AMD, which accounts for the largest share of treatment revenue, and dry AMD, which is the fastest-growing disease segment. Current standard-of-care therapies are dominated by anti-VEGF intravitreal injections, though emerging modalities are diversifying the pipeline.

• •Anti-VEGF drugs account for over 78% of total treatment revenue
• •Wet AMD dominates the market due to strong anti-VEGF therapy adoption
• •Dry AMD represents the fastest-growing disease segment

An aging global population is the foundational driver of market expansion, as AMD incidence rises sharply after age 60. Advances in long-acting anti-VEGF biologics reduce injection frequency, improving patient adherence and clinical outcomes. Complement inhibitors targeting the immune system's role in dry AMD, along with emerging gene therapies and minimally invasive drug delivery systems, are expanding the addressable market beyond current standard treatments.

• •Increasing prevalence of lifestyle and age-related eye conditions
• •Expanding healthcare spending and reimbursement coverage for specialty ophthalmic drugs
• •Technological advances in gene therapies, AI diagnostics, and sustained-release delivery

By disease type, wet AMD holds the dominant market share due to effective and widely reimbursed anti-VEGF treatments, while dry AMD is emerging as the fastest-growing segment driven by complement inhibitor approvals. Geographically, North America commands the largest revenue share, supported by advanced healthcare infrastructure, high drug adoption rates, and a sizeable elderly population. Europe and Asia-Pacific are significant markets, with the latter expected to grow as access to ophthalmic specialty care increases.

• •North America dominates global revenue share
• •Wet AMD leads current treatment market share
• •Dry AMD is the fastest-growing disease segment

What are the recent trends and outlook?

The market is shifting toward sustained-release and long-acting formulations that reduce patient clinic visits and improve adherence. Gene therapy and sustained-release implant technologies are approaching late-stage development, with potential to transform treatment paradigms. AI-assisted imaging and diagnostics are improving early detection of AMD progression, while the pipeline of complement inhibitors for dry AMD is expected to unlock a large unmet medical need over the next decade.

• •Long-acting anti-VEGF biologics and sustained-release implants are gaining traction
• •Gene therapy and complement inhibition are emerging as transformative treatment categories
• •AI-based diagnostic tools are accelerating early AMD detection and treatment monitoring